A-625 - SUPRAME: A Phase 3 trial evaluating anzutresgene autoleucel (anzu-cel, IMA203) PRAME-directed T-cell receptor T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma

Authors

• Suresh G. Nair MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

2026

Volume

4

Issue

1

Published In/Presented At

https://doi.org/10.1016/j.ejcskn.2026.100916

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division

Document Type

Article